Jan-Michael Werner
Overview
Explore the profile of Jan-Michael Werner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
465
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Friedrich M, Werner J, Steinbach J, Sabel M, Herrlinger U, Piroth M, et al.
Neurooncol Adv
. 2025 Mar;
7(1):vdaf023.
PMID: 40084168
Background: Amino acid PET using the tracer -(2-[F]fluoroethyl)-l-tyrosine (FET) is one of the most reliable imaging methods for detecting glioma recurrence. Here, we hypothesized that functional MR connectivity between the...
2.
Langen K, Stoffels G, Filss C, Kocher M, Lerche C, Sabel M, et al.
J Nucl Med
. 2025 Jan;
66(2):187-193.
PMID: 39819686
One of the most common clinical indications for amino acid PET using the tracer -(2-[F]-fluoroethyl)-l-tyrosine (F-FET) is the differentiation of tumor relapse from treatment-related changes in patients with gliomas. A...
3.
Ceccon G, Werner J, Ruge M, Goldbrunner R, Celik E, Baues C, et al.
Clin Nucl Med
. 2025 Jan;
50(4):307-315.
PMID: 39806562
Purpose: Especially in Europe, amino acid PET is increasingly integrated into multidisciplinary neuro-oncological tumor boards (MNTBs) to overcome diagnostic uncertainties such as treatment-related changes. We evaluated the accuracy of MNTB...
4.
Galldiks N, Werner J, Stetter I, Puhr H, Nakuz T, Stoffels G, et al.
Neurooncol Adv
. 2024 Dec;
6(1):vdae210.
PMID: 39737092
The phase-3 INDIGO trial demonstrated that the isocitrate dehydrogenase () inhibitor vorasidenib significantly prolonged progression-free survival and delayed intervention in patients with CNS WHO grade 2 gliomas. However, conventional MRI...
5.
Werner J, Petrescu G, Boele F, Preusser M, Platten M, Chalmers A, et al.
Neurooncol Pract
. 2024 Nov;
11(6):673-676.
PMID: 39554779
No abstract available.
6.
Laukamp K, Terzis R, Werner J, Galldiks N, Lennartz S, Maintz D, et al.
Radiology
. 2024 Jul;
312(1):e232640.
PMID: 39041936
No abstract available.
7.
Galldiks N, Lohmann P, Friedrich M, Werner J, Stetter I, Wollring M, et al.
Neuro Oncol
. 2024 Jul;
26(Supplement_9):S185-S198.
PMID: 38970818
PET imaging, particularly using amino acid tracers, has become a valuable adjunct to anatomical MRI in the clinical management of patients with glioma. Collaborative international efforts have led to the...
8.
Rosen J, Werner J, Ceccon G, Rosen E, Wollring M, Stetter I, et al.
J Nucl Med
. 2024 Apr;
65(6):838-844.
PMID: 38664020
PET using the radiolabeled amino acid -(2-[F]fluoroethyl)-l-tyrosine (F-FET) has been shown to be of value for treatment monitoring in patients with brain metastases after multimodal therapy, especially in clinical situations...
9.
Lohmann P, Gutsche R, Werner J, Jon Shah N, Langen K, Galldiks N
J Nucl Med
. 2024 Feb;
PMID: 38360054
No abstract available.
10.
Galldiks N, Albert N, Wollring M, Werner J, Lohmann P, Villanueva-Meyer J, et al.
Neurooncol Adv
. 2023 Jun;
5(Suppl 1):i84-i93.
PMID: 37287577
In patients with meningioma, diagnosis and treatment planning are predominantly based on anatomical imaging using MRI or CT. Constraints of these imaging modalities include precise meningioma delineation-especially at the skull...